-

Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has been named by U.S. News & World Report as one of the best companies to work for in healthcare.

Natera was ranked among 349 companies across 20 fields of work on factors contributing to job seekers’ decision-making when choosing a workplace that best meets their needs in their industries of interest. In healthcare specifically, Natera earned a spot on the industry list alongside companies across different elements of healthcare operations and services, including biotechnology, life sciences, pharmaceuticals, and hospital operations.

“At Natera, we are committed to fostering a positive workplace environment where employees can learn from one another, further develop in their careers, and continue to thrive – all while contributing to our very important mission,” said Steve Chapman, chief executive officer of Natera. “Natera is a great place to work because of our extremely talented employees, and we are proud to earn a spot on this list alongside so many esteemed companies across different dimensions of healthcare.”

This new recognition by U.S. News expands on the general 2023-2024 U.S. News Best Companies to Work For list by looking at how companies measure up to the expectations of their employees within their respective industries. The rankings take into account quality of pay, work-life balance, and opportunities for professional development and advancement by industry.

To calculate the U.S. News Best Companies to Work For by Industry lists, U.S. News only considered companies that were a part of the Russell 3000 index as of June 2023 and scored in the top 20% of their industry. Additionally, U.S. News required each company to have a minimum of 75 Glassdoor reviews written between 2020-2022 and grouped companies according to the Industry Classification Benchmark (ICB) used by the FTSE Russell.

To learn more about career opportunities at Natera and the core values that define company culture, please visit: www.natera.com/company/careers/.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Natera, Inc.

NASDAQ:NTRA

Release Versions

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

More News From Natera, Inc.

Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026. Across four oral presentations in muscle-invasive bladder cancer (MIBC), these data reinforce Signatera’s role in identifying patients who benefit from adjuvant immunotherapy, supporting...

Natera Reports Fourth Quarter and Full Year 2025 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Recent Financial Highlights Generated total revenues of $665.5 million in the fourth quarter of 2025, compared to $476.1 million in the fourth quarter of 2024, an increase of 39.8%. Product revenues grew 39.8% over the same period. Generated a gross margin1 of 66.9% in the fourth quar...

Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the SINERGY trial, a Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Data was recently presented in an oral plenary at the 2026 MHNCS. Approximately 73K patients are diagnosed with head and neck cancer in the U.S. annually.1 The current standard of care for R/M HNSCC patients, based on the registrational KE...
Back to Newsroom